secukinumab · Medicine question

From what age is secukinumab (Cosentyx) indicated for moderate to severe plaque psoriasis in patients who are candidates for systemic therapy?

Name: From what age is secukinumab (Cosentyx) indicated for moderate to severe plaque psoriasis in patients who are candidates for systemic therapy?
Published: 2026-11-08T02:00:53.324Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Secukinumab (Cosentyx) is indicated from age 6 years for moderate to severe plaque psoriasis in patients who are candidates for systemic therapy.

Sources for this answer

Cosentyx 150mg and 300mg solution for injection in pre-filled syringe and pre-filled penNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 29Document updated 19 August 2025

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about secukinumab